VISUDYNE (verteporfin)
OPHTHALMIC - PHOTODYNAMIC THERAPY AGENTS · CHOROIDAL NEOVASCULARIZATION ·+3
Bausch Health US
Drug class
Ophthalmic - Photodynamic Therapy Agents
Ophthalmic photodynamic therapy agents are light-activated photosensitizing drugs used in procedural ophthalmology to target and treat pathological ocular vasculature. Read more about Ophthalmic - Photodynamic Therapy Agents
2 drugs in this class 2 manufacturers
Drugs in Ophthalmic - Photodynamic Therapy Agents
VISUDYNE (verteporfin)
OPHTHALMIC - PHOTODYNAMIC THERAPY AGENTS · CHOROIDAL NEOVASCULARIZATION ·+3
BAUSCH & LOMB P
Filter & compare in the drug finder →
Opens the drug finder with Ophthalmic - Photodynamic Therapy Agents preselected. Add indication or manufacturer filters there.
Ophthalmic photodynamic therapy agents are light-activated photosensitizing drugs used in procedural ophthalmology to target and treat pathological ocular vasculature.
The primary agent in this category is intravenously administered verteporfin, which selectively accumulates in abnormal vascular endothelium and is subsequently activated by non-thermal red laser light directed into the eye.
Upon activation, the drug generates local reactive oxygen species that induce targeted endothelial damage, vessel thrombosis, and vascular occlusion while minimizing injury to surrounding normal retinal tissue.
Clinically, these agents are primarily indicated for managing subfoveal choroidal neovascularization, notably due to neovascular age-related macular degeneration, pathologic myopia, or presumed ocular histoplasmosis, as well as conditions like central serous chorioretinopathy.
-
nih.gov
Ophthalmic photodynamic therapy agents are light-activated photosensitizing drugs used in procedural ophthalmology to target and treat pathological ocular vasculature The primary agent in this category is intravenously administered verteporfin, which selectively accumulates in abnormal vascular endothelium and is subsequently activated by non-thermal red laser light directed into the eye Upon activation, the drug generates local reactive oxygen species that induce targeted endothelial damage, ve...
-
nih.gov
Ophthalmic photodynamic therapy agents are light-activated photosensitizing drugs used in procedural ophthalmology to target and treat pathological ocular vasculature The primary agent in this category is intravenously administered verteporfin, which selectively accumulates in abnormal vascular endothelium and is subsequently activated by non-thermal red laser light directed into the eye Upon activation, the drug generates local reactive oxygen species that induce targeted endothelial damage, ve...
-
wellfleetrx.com
The primary agent in this category is intravenously administered verteporfin, which selectively accumulates in abnormal vascular endothelium and is subsequently activated by non-thermal red laser light directed into the eye
-
nih.gov
Clinically, these agents are primarily indicated for managing subfoveal choroidal neovascularization, notably due to neovascular age-related macular degeneration, pathologic myopia, or presumed ocular histoplasmosis, as well as conditions like central serous chorioretinopathy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.